Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. * Diagnosis of haemophilia A in males or females, no age limitation. * New patients who have not previously been exposed to Esperoct®. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Known or suspected hypersensitivity to study product or related products. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.